Dacomitinib: Dark Horse EGFR TKI Charges into First Line Setting for Advanced NSCLC (BMIC-016)
Автор: BeaconMedIC
Загружено: 2017-11-28
Просмотров: 584
Описание:
Dr. Jack West reviews the results of the ARCHER-1050 trial that showed superior efficacy with dacomitinib vs. gefitinib in EGFR mutation-positive NSCLC. Is it too little, too late for dacomitinib, or can it find a place in a crowded first line setting?
Visit http://BeaconMedIC.com for more media & information.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: